Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 12, 2011 - Issue 17
Submit an article Journal homepage
981
Views
19
CrossRef citations to date
0
Altmetric
Reviews

Pharmacotherapy of chronic kidney disease and mineral bone disorder

Fellype Carvalho Barreto Universidade de São Paulo, Nephrology Division, Department of Internal Medicine, Av. Dr. Arnaldo, 455, 3rd floor, room 3342, 01246 903, São Paulo, Brazil+55 11 3061 8351; +55 11 3061 7261; [email protected]
, MD PhD,
Rodrigo Azevedo de Oliveira Universidade de São Paulo, Nephrology Division, Department of Internal Medicine, Av. Dr. Arnaldo, 455, 3rd floor, room 3342, 01246 903, São Paulo, Brazil+55 11 3061 8351; +55 11 3061 7261; [email protected]
, MD,
Rodrigo Bueno Oliveira Universidade de São Paulo, Nephrology Division, Department of Internal Medicine, Av. Dr. Arnaldo, 455, 3rd floor, room 3342, 01246 903, São Paulo, Brazil+55 11 3061 8351; +55 11 3061 7261; [email protected]
, MD PhD &
Vanda Jorgetti Universidade de São Paulo, Nephrology Division, Department of Internal Medicine, Av. Dr. Arnaldo, 455, 3rd floor, room 3342, 01246 903, São Paulo, Brazil+55 11 3061 8351; +55 11 3061 7261; [email protected]
, MD PhD
Pages 2627-2640 | Published online: 22 Oct 2011

Citations (19)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Stuart M. Sprague & Jürgen Floege. (2018) Sucroferric oxyhydroxide for the treatment of hyperphosphatemia. Expert Opinion on Pharmacotherapy 19:10, pages 1137-1148.
Read now
MªJesús Lloret, César Ruiz-García, Iara DaSilva, Mónica Furlano, Yaima Barreiro, José Ballarín & Jordi Bover. (2013) Lanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: a new oral powder formulation – safety, efficacy, and patient adherence. Patient Preference and Adherence 7, pages 1147-1156.
Read now

Articles from other publishers (17)

María Auxiliadora Bajo, Francisco Ríos-Moreno, Maria Dolores Arenas, Ramón Jesús Devesa-Such, Maria Jose Molina-Higueras, Margarita Delgado, Pablo Molina, Nuria García-Fernández, Alejandro Martin-Malo, Roser Peiró-Jordán, Jorge Cannata-Andia & Ángel Luis Martín-De Francisco. (2022) Safety and effectiveness of sucroferric oxyhydroxide in Spanish patients on dialysis: sub-analysis of the VERIFIE study. Nefrología (English Edition) 42:5, pages 594-606.
Crossref
María Auxiliadora Bajo, Francisco Ríos Moreno, Maria Dolores Arenas, Ramón Jesús Devesa Such, Maria Jose Molina Higueras, Margarita Delgado, Pablo Molina, Nuria García Fernández, Alejandro Martín Malo, Roser Peiró-Jordán, Jorge Cannata-Andia & Ángel Luis Martín de Francisco. (2022) Seguridad y efectividad del oxihidróxido sucroférrico en pacientes españoles en diálisis: subanálisis del estudio VERIFIE. Nefrología 42:5, pages 594-606.
Crossref
Jun‐Peng Xu, Rui‐Xiang Zeng, Peng‐Da Liao & Min‐Zhou Zhang. (2021) Effect of lanthanum carbonate on the progression of coronary artery calcification in hemodialysis patients: A meta‐analysis of randomized controlled trials. Hemodialysis International 26:2, pages 223-233.
Crossref
Daniel W. Coyne, Stuart M. Sprague, Marc Vervloet, Rosa Ramos & Kamyar Kalantar-Zadeh. (2022) Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence. Journal of Nephrology 35:3, pages 875-888.
Crossref
Paulo C. Gregório, Sergio Bucharles, Regiane S. da Cunha, Tárcio Braga, Ana Clara Almeida, Railson Henneberg, Andréa E.M. Stinghen & Fellype C. Barreto. (2021) In vitro anti-inflammatory effects of vitamin D supplementation may be blurred in hemodialysis patients. Clinics 76, pages e1821.
Crossref
Adrian C. Covic, Stuart M. Sprague, Anjay Rastogi, Markus Ketteler, Sebastian Walpen, Amandine Perrin & Jürgen Floege. (2020) Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study. Nephron 144:9, pages 428-439.
Crossref
Kristen L. Nowak & Michel Chonchol. 2020. Chronic Renal Disease. Chronic Renal Disease 1013 1033 .
Stuart M. Sprague, Markus Ketteler, Adrian C. Covic, Jürgen Floege, Viatcheslav Rakov, Sebastian Walpen & Anjay Rastogi. (2018) Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients. Hemodialysis International 22:4, pages 480-491.
Crossref
Merita Rroji, Nereida Spahia, Myftar Barbullushi & Saimir Seferi. 2018. Evolving Strategies in Peritoneal Dialysis. Evolving Strategies in Peritoneal Dialysis.
Fang Wang, Xiangxue  Lu, Jingli Zhang, Ruifang Xiong, Han Li & Shixiang Wang. (2018) Effect of Lanthanum Carbonate on All-Cause Mortality in Patients Receiving Maintenance Hemodialysis: a Meta-Analysis of Randomized Controlled Trials. Kidney and Blood Pressure Research 43:2, pages 536-544.
Crossref
Francesco Locatelli & Lucia Del Vecchio. (2017) Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?. Journal of Nephrology 30:6, pages 755-765.
Crossref
Morgan Marcuccilli, Michel Chonchol & Anna Jovanovich. (2017) Phosphate Binders and Targets Over Decades: Do We have it Right Now?. Seminars in Dialysis 30:2, pages 134-141.
Crossref
Stuart M Sprague, Morgan Marcuccilli & Viatcheslav Rakov. (2015) Clinical rationale of sucroferric oxyhydroxide for controlling hyperphosphatemia in patients with chronic kidney disease. Clinical Investigation 5:1, pages 9-21.
Crossref
Kristen L. Jablonski & Michel Chonchol. 2015. Chronic Renal Disease. Chronic Renal Disease 646 662 .
Adrian Covic & Anjay Rastogi. (2013) Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence. BMC Nephrology 14:1.
Crossref
M. Ketteler, R. P. Wuthrich & J. Floege. (2013) Management of hyperphosphataemia in chronic kidney disease--challenges and solutions. Clinical Kidney Journal 6:2, pages 128-136.
Crossref
Isabel Mercedes GarcíaLiliana AltamiranoLuciana MazzeiMiguel Fornés, Marisa Nile Molina, León FerderWalter Manucha. (2012) Role of mitochondria in paricalcitol-mediated cytoprotection during obstructive nephropathy. American Journal of Physiology-Renal Physiology 302:12, pages F1595-F1605.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.